Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) published its monthly statement of share capital and voting rights as of 04/30/2026. The table shows a total of 100,611,481 shares and 106,021,715 total voting rights.

Contact details for media and investor relations are provided.

News Market Reaction – CLLS

-2.28%

-2.28% News Effect

On the day this news was published, CLLS declined 2.28%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement provides updated figures on Cellectis’ share capital and voting rights as of April...

Analysis

This announcement provides updated figures on Cellectis’ share capital and voting rights as of April 30, 2026, continuing its regular monthly transparency on capital structure. It follows similar disclosures, such as the March 31 report showing comparable totals. In context of recent filings that emphasize ongoing losses and an effective F-3 shelf, investors may monitor how future financing decisions interact with this stable but closely watched share base.

Key Figures

Total shares: 100,611,481 Total voting rights: 106,021,715 Current share price: $3.95 +5 more

8 metrics

Total shares 100,611,481 Share capital as of 04/30/2026 on Euronext Growth

Total voting rights 106,021,715 Voting rights outstanding as of 04/30/2026

Current share price $3.95 Pre-news price for CLLS on primary U.S. listing

52-week high $5.4796 CLLS trades 27.91% below this level pre-news

52-week low $1.3271 CLLS trades 197.64% above this level pre-news

Market cap $378,222,137 Equity value prior to the April voting-rights disclosure

200-day MA $3.68 CLLS trading above this moving average before the announcement

Reporting date 04/30/2026 Reference date for share and voting-rights figures

Historical Context

5 past events · Latest: May 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Earnings timing update	Neutral	+1.6%	Announced date for Q1 2026 results release without hosting a conference call.
Apr 27	Scientific platform update	Positive	-0.3%	Presented TALE-based epigenetic editing data achieving >90% gene activity reduction.
Apr 13	Clinical trial data	Positive	-2.8%	Reported favorable interim ALPHA3 cema-cel data and potential milestone economics.
Apr 07	Capital structure update	Neutral	+5.7%	Published March 31, 2026 share-count and voting-rights totals for Euronext listing.
Mar 19	Earnings and business	Neutral	-4.0%	Released 2025 financials with higher revenue, sizable net loss and cash runway into H2 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive or science-heavy updates have sometimes seen muted or negative next-day moves, while neutral operational notices (like prior voting-rights updates) have coincided with modest gains.

Recent Company History

Over the past months, Cellectis reported full-year 2025 results with significant clinical progress but wider losses, highlighted strong CAR-T data (lasme-cel, eti-cel, cema-cel), and announced upcoming earnings dates. It also issued recurring monthly disclosures on share capital and voting rights, including one on March 31, 2026. Today’s April voting-rights update continues that pattern of routine capital-structure transparency against a backdrop of advancing clinical programs and ongoing losses.

Key Terms

isin code, euronext growth

2 terms

isin code financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.

euronext growth financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

Euronext Growth is a stock market for smaller, emerging companies that want to raise money and grow. It makes it easier for these companies to get listed and attract investors, similar to a training ground for future big businesses. This helps new companies develop and eventually become larger, more established firms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, May 06, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
04/30/2026	100,611,481	106,021,715

For further information on Cellectis, please contact:         

Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com  
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      
    
Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com   

Attachment

• Voting_Rights_PR_April_2026_EN

FAQ

How many shares did Cellectis (CLLS) report on April 30, 2026?

Direct answer: Cellectis reported 100,611,481 total shares as of April 30, 2026.

According to Cellectis, the monthly disclosure lists the total number of shares in capital and is effective for the stated date.

What were the total voting rights for Cellectis (CLLS) on April 30, 2026?

Direct answer: The company reported 106,021,715 total voting rights as of April 30, 2026.

According to Cellectis, this figure appears in the monthly voting rights table and corresponds to the reported record date.

When is the share capital and voting rights data for Cellectis (CLLS) effective?

Direct answer: The disclosure is effective as of April 30, 2026.

According to Cellectis, the table entry uses that date as the reporting cutoff for the total shares and voting rights published in the monthly update.

How can investors contact Cellectis (CLLS) for more information on share capital?

Direct answer: Investors can contact Arthur Stril, Chief Financial Officer, via investors@cellectis.com.

According to Cellectis, media contacts and investor relations phone numbers and emails are listed in the announcement for further inquiries.